ArticleMedicine2026
Association between disease awareness and prognosis in patients with glioblastoma: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate whether disease awareness among Chinese patients with glioblastoma was associated with prognosis. This single-center, retrospective cohort study included consecutive patients diagnosed with glioblastoma between February 2009 and August 2020. Disease awareness was categorized as full awareness, midway awareness, awareness of lesser severity, and unawareness based on documented medical records and follow-up information. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan-Meier and Cox regression methods, with censoring applied for patients without death or recurrence events. Ninety-three patients were included. The median age was 53 years (interquartile range [IQR], 45-64), and 57.0% were male. The patients were classified according to disease awareness category: full awareness in 25.8%, midway awareness in 26.9%, awareness of lesser severity in 21.5%, and unawareness in 25.8%. After a median follow-up of 37.81 months, the median OS was 21.11 months (95% confidence interval [CI]: 19.30-32.98), and the median RFS was 24.99 months (95% CI: 16.01-not estimable). Disease awareness was not significantly associated with OS or RFS after adjustment for potential confounders, including treatments. Midway awareness showed a nonsignificant numerical pattern toward longer OS (hazard ratio, 0.631; 95% CI: 0.331-1.204; P = .163). Disease awareness level was not significantly associated with OS or RFS in this cohort. The numerically longer OS observed among patients with midway awareness should be interpreted as exploratory and hypothesis-generating and requires confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.